Valneva (VLA) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
16 Nov, 2026Lyme disease program and regulatory path
Phase III efficacy was 73.2%; the primary analysis narrowly missed its prespecified confidence-interval threshold, while a second prespecified analysis including one additional placebo case cleared it. The safety profile was described as excellent.
EMA review clearance was completed and the application submitted and accepted; a Health Canada submission followed. Pfizer is leading ongoing FDA discussions on the BLA data package and post-marketing requirements.
The proposed U.S. licensure package combines the totality of clinical evidence, including a correlate-of-risk analysis linking immunogenicity to Lyme cases, case reviews over time and booster data, plus risk-benefit and health-economic analyses.
BLA timing shifted as FDA discussions continue on evidence and post-marketing requirements, which Lingelbach said FDA expects resolved before submission. He hoped for submission before Christmas 2026; delay could risk losing a commercial year due to Lyme seasonality.
A VRBPAC meeting is assumed; Lingelbach expressed confidence in a positive outcome, with risk-benefit, health-economic benefit and the totality of evidence expected to be central. No additional FDA study was anticipated.
Lyme commercial outlook
European licensure remains expected in fall 2027, with a possible launch in key countries that fall; Pfizer’s tick-disease and TBE commercial capabilities were cited as potential support for a launch.
In Europe, an initial launch phase may precede final vaccine recommendations, which can take time; reimbursement in some EU countries was discussed as a 9–12-month process.
Pfizer has publicly projected annual sales north of $1B; market analyses cited a $1B–$3B opportunity. High-risk populations were stated as more than 200M in Europe and 80M–90M in the U.S.
Shigella and pipeline priorities
The adult controlled human infection model met its primary endpoint, and the infant study showed significant anti-LPS IgG increases across four serotypes; the challenge model worked and immunogenicity correlated with efficacy.
Shigella responses were inconsistent across participants, indicating a need to optimize dose and schedule. Studies are being planned but will not start until there is greater Lyme clarity and funding certainty; progression in adults and children could resume thereafter.
Shigella could advance to its next development stage in late 2027. Clinical entry for EBV has been slowed; the EBV asset was described as differentiated, with potential to explore enteric combination vaccines.
Latest events from Valneva
- LB6V’s Phase 3 results and pending reviews anchor growth plans and conditional 2027 self-sustainability.VLA
Company presentation - Sales grew as IXCHIQ launched and the Lyme vaccine advanced through Phase 3.VLA
Q4 2023 - Revenue and product sales fell, but cash position improved and 2026 guidance reaffirmed.VLA
Q2 2026 - Late-stage Lyme vaccine, strong pipeline, and €135–€150m 2026 sales guide strategic growth.VLA
Company presentation - 2025 revenues hit €174.7m, proprietary sales rose 9%, and key vaccine milestones are ahead.VLA
Q4 2025 - Revenue up 8.9% to €127M; net loss widens, but financial flexibility and guidance reaffirmed.VLA
Q3 2025 - Revenue up 37.8% to €97.6M; strong vaccine sales, reduced cash burn, and key milestones achieved.VLA
Q2 2025 - Net profit of €24.7M, strong vaccine sales, and pipeline progress support positive outlook.VLA
Q3 2024 - Q1 2025 revenue up 50% with strong vaccine sales, margin gains, and pipeline progress.VLA
Q1 2025